BJMO - volume 10, issue 2, april 2016
B. Dekeyser MD, M. Haagdorens MD, I. Deleu MD, E. Van Hul MD, E. Beerens MD, D. Van der Planken MD, K. Hendrickx MD, L. Verstraeten MD, Y. Geussens MD, W. Lybaert MD
A 54-year old man presented with a new-onset headache, phonophobia, tinnitus, blurred vision, and nausea. Further imaging and histological examination confirmed the diagnosis of an olfactory neuroblastoma. Olfactory neuroblastoma or esthesioneuroblastoma is a rare type of cancer, originating from the basal stem cells of the olfactory epithelium in the nasal cavity. The patient received a maximal possible surgical resection of the tumour, followed by adjuvant chemo-irradiation. Given the absence of neck metastases, no prophylactic treatment of the neck was done. Recent studies state that standard treatment of esthe-sioneuroblastoma consists of surgical resection, followed by local radiotherapy. Adjuvant chemotherapy is recommended for the locally advanced tumours. As for the treatment of the neck, current consensus is to perform salvage therapy when neck metastases are present.
(BELG J MED ONCOL 2016;10(2):69–72)
Read moreBJMO - volume 9, issue 2, may 2015
I. Elalamy MD, PhD, J-L. Canon MD, PhD, A. Bols MD, PhD, W. Lybaert MD, L. Duck MD, PhD, K. Jochmans MD, PhD, L. Bosquée MD, PhD, M. Peeters MD, PhD, A. Awada MD, PhD, P. Clement MD, PhD, S. Holbrechts MD, PhD, J.F. Baurain MD, PhD, J. Mebis MD, PhD, J. Nortier MD, PhD
Venous thromboembolism is a frequent cause of mortality and morbidity in patients with malignancy. Thrombosis is one of the leading causes of death in patients with malignancy after cancer itself. As such, prompt recognition and treatment of venous thromboembolism are required in order to reduce the risk of venous thromboembolism-related mortality. This report reviews the interrelationship between cancer, renal insufficiency and venous thromboembolism. The working group behind this review article concludes that low molecular weight heparins decrease the risk of recurrent venous thrombosis in cancer patients without increasing major bleeding complications. Low molecular weight heparins are therefore recommended as first line antithrombotic treatment in cancer patients with a clear clinical benefit. In patients with renal dysfunction, who are at increased risk of bleeding and of thrombotic complications, preference should be given to unfractionated heparin or a low molecular weight heparin with a mean molecular weight such as tinzaparin, having less risk of plasma accumulation and offering the possibility to maintain full therapeutic dose.
(BELG J MED ONCOL 2015;9(2):53–60)
Read moreBJMO - volume 6, issue 4, september 2012
J.F. Baurain MD, PhD, W. Lybaert MD
It has become a tradition to hold the biennial International Conference on Thrombosis and Haemostasis Issues in Cancer (ICTHIC) in Bergamo. Bergamo is a quiet town in Northern Italy located on a hilltop beyond the Alps. Over 700 physicians with different backgrounds but the same interest attended the meeting this year from April 20th to April 22nd. The meeting provides a unique opportunity for reviewing the different molecular and clinical findings on thrombosis and haemostasis issues in cancer and for updating the guidelines on prophylaxis and treatment of Venous Thrombo-Embolic Events (VTE) in cancer patients. This congress report covers several key topics: duration of prophylaxis in cancer patients undergoing surgery, prevention in medical cancer patients, type and duration of VTE treatment in cancer patients, place of the newer anti-thrombotic agents in cancer patients and survival advantage of Low-Weight Molecular Heparins (LWMH). (BELG J MED ONCOL 2012;6:140–143)
Read more
Top
